Francisella tularensis vaccines

Vaccine

Volumn 27, Issue SUPPL. 4, 2009, Pages

  Oyston, Petra C F ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Francisella; Vaccines

Indexed keywords

LIVE VACCINE; SUBUNIT VACCINE;

AEROSOL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; DISEASE SEVERITY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; EXPERIMENTAL ANIMAL; FRANCISELLA TULARENSIS; HUMAN; IMMUNIZATION; INFECTION PREVENTION; LICENSING; NONHUMAN; PRIORITY JOURNAL; TULAREMIA;

EID: 78149353989     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.090     Document Type: Article

References (46)

1. Sjostedt A. Family XVII. FRANCISELLACEAE, Genus I. Francisella. In: Brenner DJ, Krieg NR, Staley JT, Garrity GM, editors. Bergey's manual of sytematic bacteriology. New York: Springer-Verlag; 2005.
2. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285(21):2763-73.
3. World Health Organisation. Health aspects of chemical and biological weapons. Geneva: WHO; 1970.
4. Foshay L. Tularemia. Annu Rev Microbiol 1950;4:313-30.
5. Van Metre TE, Kadull PJ. Laboratory-acquired tularemia in vaccinated individuals: a report of 62 cases. Ann Internal Med 1959;50:621-32.
6. Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis 1989;11(3):440-51.
7. Conlan JW, Shen H, Webb A, Perry MB. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 2002;20(29-30):3465-71.
8. Fulop M, Manchee R, Titball R. Role of lipopolysaccharide and a major outermembrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 1995;13(13):1220-5.
9. Fulop M, Mastroeni P, Green M, Titball RW. Role of antibody to lipopolysaccharide in protection against low-and high-virulence strains of Francisella tularensis. Vaccine 2001;19(31):4465-72.
10. Eyles JE, Hartley MG, Laws TR, Oyston PCF, Griffin KF, Titball RW. Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS). Microb Pathogen 2008;44(2):164-8.
11. Jia QM, Lee BY, Clemens DL, Bowen RA, Horwitz MA. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine 2009;27(8):1216-29.
12. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999;162(4):2291-8.
13. Lembo A, Pelletier M, Iyer R, Timko M, Dudda JC, West TE, et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol 2008;180(11):7574-81.
14. Troyer RM, Propst KL, Fairman J, Bosio CM, Dow SW. Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine 2009;27:4424-33.
15. Titball RW, Oyston PCF. A vaccine for tularaemia. Exp Opin Biol Ther 2003;3(4):645-53.
16. Eigelsbach HT, Downs CM. Prophylactic effectiveness of live and killed tularemia vaccines, I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol 1961;87:415-25.
17. Sandstrom G. The tularemia vaccine. J Chem Tech Biotechnol 1994;59:315-20.
18. Hornick RB, Eigelsbach HT. Aerogenic immunization of man with live tularemia vaccine. Bacteriol Rev 1966;30:532-8.
19. Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. Tularemia vaccine study, I. Intracutaneous challenge. Arch Intern Med 1961;107:689-701.
20. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study, II. Respiratory challenge. Arch Intern Med 1961;107:702-14.
21. Hepburn MJ, Purcell BK, Lawler JV, Coyne SR, Petitt PL, Sellers KD, et al. Live vaccine strain Francisella tularensis is detectable at the inoculation site but not in blood after vaccination against tularemia. Clin Infect Dis 2006;43(6): 711-6.
22. Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immunity to Francisella. Ann NY Acad Sci 2007;1105:284-324.
23. Poquet Y, Kroca M, Halary F, Stenmark S, Peyrat MA, Bonneville M, et al. Expansion of V gamma 9V delta 2 T cells is triggered by Francisella tularensisderived phosphoantigens in tularemia but not after tularemia vaccination. Infect Immun 1998;66(5):2107-14.
24. Griffin KF, Oyston PCF, Titball RW. Francisella tularensis vaccines. Fems Immunol Med Microbiol 2007;49(3):315-23.
25. Ericsson M, Sandstrom G, Sjostedt A, Tarnvik A. Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. J Infect Dis 1994;170:110-4.
26. Pasetti MF, Cuberos L, Horn TL, Shearer JD, Matthews SJ, House RV, et al. An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. Vaccine 2008;26(14):1773-85.
27. Petrosino JF, Xiang Q, Karpathy SE, Jiang H, Yerrapragada S, Liu Y, et al. Chromosome rearrangement and diversification of Francisella tularensis revealed by the type B (OSU18) genome sequence. J Bacteriol 2006;188(19):6977-85.
28. Rohmer L, Brittnacher M, Svensson K, Buckley D, Haugen E, Zhou Y, et al. Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison. Infect Immun 2006;74(12):6895-906.
29. Forslund AL, Kuoppa K, Svensson K, Salomonsson E, Johansson A, Bystrom M, et al. Direct repeat-mediated deletion of a type IV pilin gene results in major virulence attenuation of Francisella tularensis. Mol Microbiol 2006;59(6): 1818-30.
30. Twine S, Bystrom M, Chen WX, Forsman M, Golovliov I, Johansson A, et al. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun 2005;73(12):8345-52.
31. Salomonsson E, Kuoppa K, Forslund AL, Zingmark C, Golovliov I, Noppa L, et al. Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain (LVS) of Francisella tularensis. Infect Immun; in press.
32. Larsson P, Oyston PCF, Chain P, Chu MC, Duffield M, Fuxelius HH, et al. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet 2005;37:153-9.
33. Prior RG, Klasson L, Larsson P, Williams K, Lindler L, Sjöstedt A, et al. Preliminary analysis and annotation of the partial genome sequence of Francisella tularensis strain Schu S4. J Appl Microbiol 2001;91(4):614-20.
34. Quarry JE, Isherwood K, Michell SL, Diaper H, Titball RW, Oyston PCF. A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice. Vaccine 2007;27:2011-8.
35. Gray CG, Cowley SC, Cheung KKM, Nano FE. The identification of five genetic loci of Francisella novicida associated with intracellular growth. FEMS Microbiol Lett 2002;215(1):53-6.
36. Telepnev M, Golovliov I, Grundstrom T, Tarnvik A, Sjostedt A. Francisella tularensis inhibits Toll-like receptor-mediated activation of intracellular signalling and secretion of TNF-alpha and IL-1 from murine macrophages. Cell Microbiol 2003;5(1):41-51.
37. Hager AJ, Bolton DL, Pelletier MR, Brittnacher MJ, Gallagher LA, Kaul R, et al. Type IV pili-mediated secretion modulates Francisella virulence. Mol Microbiol 2006;62(1):227-37.
38. Lee BY, Horwitz MA, Clemens DL. Identification, recombinant expression, immuno localization in macrophages, and T-cell responsiveness of the major extracellular proteins of Francisella tularensis. Infect Immun 2006;74(7):4002-13.
39. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 1991;59(9):2922-8.
40. Tulis JJ, Eigelsbach HT, Kerpsack RW. Host-parasite relationship in monkeys administered live tularemia vaccine. Am J Pathol 1970;58:329-36.
41. Lyons CR, Wu TH. Animal models of Francisella tularensis infection. In: Kwaik YA, Metzger DW, Nano F, Sjostedt A, Titball R, editors. Francisella tularensis: biology, pathogenicity, epidemiology and biodefense; 2007. p. 238-65.
42. Raymond CR, Conlan JW. Differential susceptibility of Sprague-Dawley and Fischer 344 rats to infection by Francisella tularensis. Microb Pathogen 2009;46(4):231-4.
43. Schricke RL, Hall WC, Mitten JQ, Eigelsbach HT. Pathogenesis of tularemia in monkeys aerogenically exposed to Francisella tularensis 425. Infect Immun 1972;5(5):734-44.
44. Hall WC, Kovatch RM, Schreicker RL. Tularaemic pneumonia: pathogenesis of the aerosol-induced disease in monkeys. J Pathol 1973;110:193-201.
45. Nelson M, Lever MS, Savage VL, Salguero FJ, Pearce PC, Stevens DJ, et al. Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus). Int J Exp Pathol 2009;90(2):109-18.